Kyntra Bio Receives Nasdaq Delisting Notice for Non-Compliance with Listing Standards

summarizeSummary

Kyntra Bio, Inc. received a notice from Nasdaq indicating non-compliance with continued listing requirements related to total assets and revenue, potentially leading to delisting from the Nasdaq Global Select Market.

check_boxKey Events

• Nasdaq Non-Compliance Notice Received

  Kyntra Bio received a letter on April 2, 2026, from Nasdaq, notifying the company of non-compliance with the Nasdaq Global Select Market's continued listing requirements for total assets and revenue.

• Reason for Non-Compliance

  The non-compliance is attributed to the revenue of FibroGen International being presented as held for sale (in discontinued operations) in 2024 and 2025, impacting the required financial metrics.

• No Immediate Delisting

  The notification has no immediate effect on the listing of Kyntra Bio's common stock on Nasdaq.

• Compliance Plan and Potential Extension

  The company has 45 days (until May 18, 2026) to submit a plan to regain compliance, with a potential extension of up to 180 days (September 29, 2026) if the plan is accepted.

auto_awesomeAnalysis

This 8-K reports a significant risk event for Kyntra Bio. While the notice does not result in immediate delisting, it formally identifies the company's failure to meet Nasdaq Global Select Market's continued listing standards for total assets and revenue. The issue stems from the presentation of FibroGen International's revenue as discontinued operations, impacting the company's reported financial metrics. Kyntra Bio has 45 days to submit a compliance plan and could receive an extension, or may consider transferring to the Nasdaq Capital Market. This development introduces uncertainty regarding the company's future listing status and could negatively impact investor confidence and stock liquidity, despite the recent 10-K indicating improved financial stability.